TARGACEPT, INC.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
- Website
- http://www.targacept.com
Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02187094
- Locations
- 🇺🇸
Horizon Research Group, Inc., Mobile, Alabama, United States
🇺🇸Prefered Research Partners, Inc., Little Rock, Arkansas, United States
🇺🇸Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 1635
- Registration Number
- NCT01868516
- Locations
- 🇺🇸
Simon-Williamson Clinic, P.C., Birmingham, Alabama, United States
🇺🇸Physician's Resource Group, Dothan, Alabama, United States
🇺🇸Coastal Clinical Research, Inc., Mobile, Alabama, United States
Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia
- Conditions
- Cognitive DysfunctionSchizophreniaNegative Symptoms
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-12-08
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 603
- Registration Number
- NCT01488929
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Inc, Garden Grove, California, United States
🇺🇸Behavorial Research Specialists, Glendale, California, United States
🇺🇸Apostle Clinical Trials, Inc, Long Beach, California, United States
Safety & Efficacy of TC-5619 in Adults With Inattentive-predominant Attention Deficit/Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Drug: TC-5619-238 25mgDrug: PlaceboDrug: TC-5619-238 5mg
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2013-04-30
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 250
- Registration Number
- NCT01472991
- Locations
- 🇺🇸
Southwestern Research, Inc, Beverly Hills, California, United States
🇺🇸Synergy Clinical Research Center, National City, California, United States
🇺🇸MCB Clinical Research Centers, LLC, Colorado Springs, Colorado, United States
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 386
- Registration Number
- NCT01466088
- Locations
- 🇺🇸
Banner Alzheimer Institute, Phoenix, Arizona, United States
🇺🇸Meridien Research, Brooksville, Florida, United States
🇺🇸MD Clinical, Hallandale Beach, Florida, United States
TC-6987 for the Treatment of Mild to Moderate Asthma
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT01296087
- Locations
- 🇺🇸
Clinical research Center of Alabama, Birmingham, Alabama, United States
🇺🇸Medical Research of Arizona, Scottsdale, Arizona, United States
🇺🇸California Allergy and Asthma Medical Group, Inc., Los Angeles, California, United States
Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus
- First Posted Date
- 2011-02-10
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT01293669
- Locations
- 🇺🇸
Clopton Clinic, Jonesboro, Arkansas, United States
🇺🇸NCA Medical Center, Mountain Home, Arkansas, United States
🇺🇸Associated Pharmaceutical Research Center, Buena Park, California, United States
Multiple Ascending Dose Study of TC-5619 in Healthy Elderly Subjects and Subjects With Alzheimer's Disease
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01254448
- Locations
- 🇺🇸
Collaborative Neuroscience Network, Long Beach, California, United States
🇺🇸San Francisco Clinical Research Center, San Francisco, California, United States
🇺🇸MD Clinical, Hallandale Beach, Florida, United States
Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2013-12-02
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01149200
- Locations
- 🇬🇧
Quotient Clinical Ltd, Ruddington, United Kingdom
Efficacy, Safety, and Tolerability of TC-5619 in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Targacept Inc.
- Target Recruit Count
- 134
- Registration Number
- NCT01124708
- Locations
- 🇺🇸
Florida Clinical Research Center, LLC, Maitland, Florida, United States
🇺🇸Clinical Neuroscience Solutions, Inc., Memphis, Tennessee, United States
🇺🇸Fidelity Clinical Research, Inc, Lauderhill, Florida, United States